{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:46:03Z","timestamp":1792165563367,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-024-02073-2","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T07:02:16Z","timestamp":1728111736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential"],"prefix":"10.1186","volume":"29","author":[{"given":"Aswathy R.","family":"Devan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyalakshmi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind K.","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshini","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balachandran S.","family":"Vinod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekshmi R.","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"3","key":"2073_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2073_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cld.782","volume":"13","author":"A Likhitsup","year":"2019","unstructured":"Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis. 2019;13(1):13.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"2073_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):1\u20133.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2073_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","volume":"25","author":"MS Grandhi","year":"2016","unstructured":"Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74\u201385.","journal-title":"Surg Oncol"},{"issue":"2","key":"2073_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cas.14251","volume":"111","author":"Y Shimizu","year":"2020","unstructured":"Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2020;111(2):334\u201342.","journal-title":"Cancer Sci"},{"issue":"9","key":"2073_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/cancers11091339","volume":"11","author":"T Nishida","year":"2019","unstructured":"Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers. 2019;11(9):1339.","journal-title":"Cancers"},{"issue":"2","key":"2073_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s13337-019-00517-6","volume":"30","author":"B Moudi","year":"2019","unstructured":"Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease. 2019;30(2):193\u2013200.","journal-title":"Virusdisease"},{"issue":"4","key":"2073_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.30646","volume":"70","author":"N Li","year":"2019","unstructured":"Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y. A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70(4):1231\u201345.","journal-title":"Hepatology"},{"issue":"3","key":"2073_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3892\/or.2017.5387","volume":"37","author":"M Montalbano","year":"2017","unstructured":"Montalbano M, Georgiadis J, Masterson AL, McGuire JT, Prajapati J, Shirafkan A, Rastellini C, Cicalese L. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma. Oncol Rep. 2017;37(3):1291\u2013300.","journal-title":"Oncol Rep"},{"issue":"6","key":"2073_CR10","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3892\/mmr.2014.2600","volume":"10","author":"XH Qi","year":"2014","unstructured":"Qi XH, Wu D, Cui HX, Ma N, Su J, Wang YT, Jiang YH. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 2014;10(6):3177\u201384.","journal-title":"Mol Med Rep"},{"issue":"7","key":"2073_CR11","first-page":"1565","volume":"127","author":"M Capurro","year":"2014","unstructured":"Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 2014;127(7):1565\u201375.","journal-title":"J Cell Sci"},{"issue":"1","key":"2073_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/clinpract11010012","volume":"11","author":"T Reischer","year":"2021","unstructured":"Reischer T, Laccone F, Kasprian GJ, Yerlikaya-Schatten G. Simpson\u2013Golabi\u2013Behmel-syndrome in dichorionic-diamniotic twin pregnancy. Clin Pract. 2021;11(1):75\u201380.","journal-title":"Clin Pract"},{"issue":"35","key":"2073_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.matbio.2013.12.007","volume":"1","author":"J Filmus","year":"2014","unstructured":"Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol. 2014;1(35):248\u201352.","journal-title":"Matrix Biol"},{"issue":"9","key":"2073_CR14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fonc.2019.00708","volume":"2","author":"A Kolluri","year":"2019","unstructured":"Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019;2(9):708.","journal-title":"Front Oncol"},{"issue":"4","key":"2073_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.livres.2020.11.003","volume":"4","author":"TC Shih","year":"2020","unstructured":"Shih TC, Wang L, Wang HC, Wan YJ. Glypican-3: a molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Res. 2020;4(4):168\u201372.","journal-title":"Liver Res"},{"issue":"9","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","volume":"188","author":"KL Moek","year":"2018","unstructured":"Moek KL, Fehrmann RS, van der Vegt B, de Vries EG, de Groot DJ. Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database. Am J Pathol. 2018;188(9):1973\u201381.","journal-title":"Am J Pathol"},{"issue":"1","key":"2073_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-017-0146-5","volume":"6","author":"C Chen","year":"2017","unstructured":"Chen C, Huang X, Ying Z, Wu D, Yu Y, Wang X, Chen C. Can glypican-3 be a disease-specific biomarker? Clin Transl Med. 2017;6(1):1\u20136.","journal-title":"Clin Transl Med"},{"issue":"25","key":"2073_CR18","doi-asserted-by":"publisher","first-page":"41211","DOI":"10.18632\/oncotarget.17162","volume":"8","author":"F Cartier","year":"2017","unstructured":"Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Tr\u00e9z\u00e9guet V, Sagliocco F, Hagedorn M. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget. 2017;8(25):41211.","journal-title":"Oncotarget"},{"issue":"9","key":"2073_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2019.00248","volume":"10","author":"Y Shimizu","year":"2019","unstructured":"Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Front Oncol. 2019;10(9):248.","journal-title":"Front Oncol"},{"issue":"168","key":"2073_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bcp.2019.06.020","volume":"1","author":"SP Kaur","year":"2019","unstructured":"Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;1(168):108\u201318.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2073_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","volume":"38","author":"F Zhou","year":"2018","unstructured":"Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38(2):741\u201367.","journal-title":"Med Res Rev"},{"issue":"1","key":"2073_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02462-1","volume":"18","author":"X Liu","year":"2020","unstructured":"Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M, Gou L, Ho M, Jia S, Chen F, Gao W. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med. 2020;18(1):1\u20132.","journal-title":"J Transl Med"},{"key":"2073_CR23","unstructured":"Casale J, Crane JS. Biochemistry, Glycosaminoglycans."},{"issue":"5","key":"2073_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/med.21429","volume":"37","author":"G Ghiselli","year":"2017","unstructured":"Ghiselli G. Drug-mediated regulation of glycosaminoglycan biosynthesis. Med Res Rev. 2017;37(5):1051\u201394.","journal-title":"Med Res Rev"},{"issue":"93","key":"2073_CR25","first-page":"1","volume":"1","author":"L Zhang","year":"2010","unstructured":"Zhang L. Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog Mol Biol Transl Sci. 2010;1(93):1\u20137.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"2073_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1194\/jlr.E065417","volume":"57","author":"T Kinoshita","year":"2016","unstructured":"Kinoshita T. Glycosylphosphatidylinositol (GPI) anchors: biochemistry and cell biology: introduction to a thematic review series. J Lipid Res. 2016;57(1):4\u20135.","journal-title":"J Lipid Res"},{"issue":"3","key":"2073_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/09687688.2011.562557","volume":"28","author":"G M\u00fcller","year":"2011","unstructured":"M\u00fcller G. Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology. Mol Membr Biol. 2011;28(3):187\u2013205.","journal-title":"Mol Membr Biol"},{"issue":"7542","key":"2073_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature14259","volume":"519","author":"S Kakugawa","year":"2015","unstructured":"Kakugawa S, Langton PF, Zebisch M, Howell SA, Chang TH, Liu Y, Feizi T, Bineva G, O\u2019Reilly N, Snijders AP, Jones EY. Notum deacylates Wnt proteins to suppress signalling activity. Nature. 2015;519(7542):187\u201392.","journal-title":"Nature"},{"issue":"6","key":"2073_CR29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ijc.24941","volume":"126","author":"SI Zittermann","year":"2010","unstructured":"Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 2010;126(6):1291\u2013301.","journal-title":"Int J Cancer"},{"issue":"7","key":"2073_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1021\/acs.biochem.7b01208","volume":"57","author":"A Saad","year":"2018","unstructured":"Saad A, Liet B, Joucla G, Santarelli X, Charpentier J, Claverol S, Grosset CF, Tr\u00e9z\u00e9guet V. Role of glycanation and convertase maturation of soluble glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry. 2018;57(7):1201\u201311.","journal-title":"Biochemistry"},{"issue":"1","key":"2073_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-019-0342-7","volume":"9","author":"Z Tian","year":"2019","unstructured":"Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9(1):1.","journal-title":"Cell Biosci"},{"issue":"3","key":"2073_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2014.10.029","volume":"62","author":"OW Yeung","year":"2015","unstructured":"Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607\u201316.","journal-title":"J Hepatol"},{"issue":"24","key":"2073_CR33","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.4161\/cbt.8.24.9985","volume":"8","author":"H Takai","year":"2009","unstructured":"Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T, Kato A, Suzuki M. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biol Ther. 2009;8(24):2329\u201338.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2073_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):1\u20132.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2073_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40883-019-00113-6","volume":"6","author":"N Parayath","year":"2020","unstructured":"Parayath N, Padmakumar S, Nair SV, Menon D, Amiji MM. Strategies for targeting cancer immunotherapy through modulation of the tumor microenvironment. Regen Eng Transl Med. 2020;6(1):29\u201349.","journal-title":"Regen Eng Transl Med"},{"key":"2073_CR36","doi-asserted-by":"crossref","unstructured":"Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 enhances reprogramming of glucose metabolism in liver cancer cells. BioMed Res Int. 2019;2019.","DOI":"10.1155\/2019\/2560650"},{"issue":"6","key":"2073_CR37","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/cancers12061668","volume":"12","author":"M Mossenta","year":"2020","unstructured":"Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers. 2020;12(6):1668.","journal-title":"Cancers"},{"issue":"1","key":"2073_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-019-4778-y","volume":"12","author":"K Yorita","year":"2019","unstructured":"Yorita K, Ohno A, Nishida T, Kondo K, Ohtomo T, Kataoka H. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res Notes. 2019;12(1):1\u20137.","journal-title":"BMC Res Notes"},{"issue":"3","key":"2073_CR39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijo.2015.2827","volume":"46","author":"Y Wu","year":"2015","unstructured":"Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG. Glypican-3 promotes epithelial\u2013mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol. 2015;46(3):1275\u201385.","journal-title":"Int J Oncol"},{"issue":"4","key":"2073_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","volume":"35","author":"CL Chaffer","year":"2016","unstructured":"Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645\u201354.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"2073_CR41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798\u2013808.","journal-title":"J Hepatol"},{"issue":"5","key":"2073_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1129483","volume":"5","author":"Y Sawada","year":"2016","unstructured":"Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M. Phase II study of the GPC-3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5(5): e1129483.","journal-title":"Oncoimmunology"},{"key":"2073_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JHC.S116513","volume":"3","author":"Y Wu","year":"2016","unstructured":"Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocellular Carcinoma. 2016;3:63.","journal-title":"J Hepatocellular Carcinoma"},{"issue":"13","key":"2073_CR44","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.7150\/thno.44789","volume":"10","author":"N Yang","year":"2020","unstructured":"Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, Yao B, Wang Y, Yang W, Liu Q, Tu K. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics. 2020;10(13):5790.","journal-title":"Theranostics"},{"issue":"15","key":"2073_CR45","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-16-2131","volume":"23","author":"J Xu","year":"2017","unstructured":"Xu J, Liang J, Meng YM, Yan J, Yu XJ, Liu CQ, Xu L, Zhuang SM, Zheng L. Vascular CXCR4 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma. Clin Cancer Res. 2017;23(15):4482\u201392.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2073_CR46","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3892\/ol.2017.6396","volume":"14","author":"KS Jeng","year":"2017","unstructured":"Jeng KS, Jeng CJ, Jeng WJ, Chang CF, Sheen I. Role of CXC chemokine ligand 12\/CXC chemokine receptor 4 in the progression of hepatocellular carcinoma. Oncol Lett. 2017;14(2):1905\u201310.","journal-title":"Oncol Lett"},{"issue":"4","key":"2073_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.bbrc.2012.02.069","volume":"419","author":"S Liu","year":"2012","unstructured":"Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J, Zeng X. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012;419(4):656\u201361.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2073_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","volume":"16","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol. 2022;16(12): 824208.","journal-title":"Front Oncol"},{"issue":"3","key":"2073_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1515\/hsz-2015-0265","volume":"397","author":"MM Al-Gayyar","year":"2016","unstructured":"Al-Gayyar MM, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma. Biol Chem. 2016;397(3):257\u201367.","journal-title":"Biol Chem"},{"issue":"5","key":"2073_CR50","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/hep.23848","volume":"52","author":"JP Lai","year":"2010","unstructured":"Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3\u2013dependent Wnt activation. Hepatology. 2010;52(5):1680\u20139.","journal-title":"Hepatology"},{"issue":"10","key":"2073_CR51","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/j.1478-3231.2010.02336.x","volume":"30","author":"JP Lai","year":"2010","unstructured":"Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int. 2010;30(10):1522\u20138.","journal-title":"Liver Int"},{"issue":"1","key":"2073_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.dld.2018.06.012","volume":"51","author":"P Hu","year":"2019","unstructured":"Hu P, Ke C, Guo X, Ren P, Tong Y, Luo S, et al. Both glypican-3\/Wnt\/\u03b2-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. Dig Liver Dis. 2019;51(1):120\u20136.","journal-title":"Dig Liver Dis"},{"issue":"14","key":"2073_CR53","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2174\/1389557515666150101105135","volume":"14","author":"Z Dong","year":"2014","unstructured":"Dong Z, Yao M, Wang L, Yang J, Yao D. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem. 2014;14(14):1183\u201393.","journal-title":"Mini Rev Med Chem"},{"issue":"5","key":"2073_CR54","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1535-7163.MCT-14-1038","volume":"14","author":"B Madan","year":"2015","unstructured":"Madan B, Virshup DM. Targeting Wnts at the source\u2014new mechanisms, new biomarkers, new drugs. Mol Cancer Ther. 2015;14(5):1087\u201394.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2073_CR55","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461\u201373.","journal-title":"Oncogene"},{"issue":"6","key":"2073_CR56","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.devcel.2016.08.011","volume":"38","author":"KM Loh","year":"2016","unstructured":"Loh KM, van Amerongen R, Nusse R. Generating cellular diversity and spatial form: Wnt signaling and the evolution of multicellular animals. Dev Cell. 2016;38(6):643\u201355.","journal-title":"Dev Cell"},{"issue":"5","key":"2073_CR57","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.16748","volume":"23","author":"P Kafri","year":"2016","unstructured":"Kafri P, Hasenson SE, Kanter I, Sheinberger J, Kinor N, Yunger S, Shav-Tal Y. Quantifying \u03b2-catenin subcellular dynamics and cyclin D1 mRNA transcription during Wnt signaling in single living cells. Elife. 2016;23(5): e16748.","journal-title":"Elife"},{"issue":"5","key":"2073_CR58","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-15-1447","volume":"22","author":"BH Sohn","year":"2016","unstructured":"Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2016;22(5):1256\u201364.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2073_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/abbs\/gmu106","volume":"47","author":"L Hong","year":"2015","unstructured":"Hong L, Cai Y, Jiang M, Zhou D, Chen L. The Hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin. 2015;47(1):46\u201352.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2073_CR60","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2147\/CMAR.S230466","volume":"12","author":"L Mi","year":"2020","unstructured":"Mi L, Kuang H. Melatonin regulates cisplatin resistance and glucose metabolism through hippo signaling in hepatocellular carcinoma cells. Cancer Manag Res. 2020;12:1863.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2073_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1478-3231.2011.02646.x","volume":"32","author":"H Li","year":"2012","unstructured":"Li H, Wolfe A, Septer S, Edwards G, Zhong X, Bashar Abdulkarim A, Ranganathan S, Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2012;32(1):38\u201347.","journal-title":"Liver Int"},{"issue":"3","key":"2073_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/gad.294348.116","volume":"31","author":"X Guo","year":"2017","unstructured":"Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, Ji X, Ji F, Gong XG, Li L, Bai X. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017;31(3):247\u201359.","journal-title":"Genes Dev"},{"issue":"12","key":"2073_CR63","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1369\/0022155420933709","volume":"68","author":"N Li","year":"2020","unstructured":"Li N, Spetz MR, Ho M. The role of Glypicans in cancer progression and therapy. J Histochem Cytochem. 2020;68(12):841\u201362.","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"2073_CR64","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/ijms22041931","volume":"22","author":"MH Ngo","year":"2021","unstructured":"Ngo MH, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The role of igf\/igf-1r signaling in hepatocellular carcinomas: stemness-related properties and drug resistance. Int J Mol Sci. 2021;22(4):1931.","journal-title":"Int J Mol Sci"},{"issue":"46","key":"2073_CR65","doi-asserted-by":"publisher","first-page":"80429","DOI":"10.18632\/oncotarget.19035","volume":"8","author":"W Cheng","year":"2017","unstructured":"Cheng W, Huang PC, Chao HM, Jeng YM, Hsu HC, Pan HW, Hwu WL, Lee YM. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. Oncotarget. 2017;8(46):80429.","journal-title":"Oncotarget"},{"key":"2073_CR66","unstructured":"Wang J, Roncal OA, Ittmann MM, Ye Y. Evaluation of Glypican-3 expression in poorly differentiated carcinomas of lung origin. North Am J Med Sci. 2020;13(1)."},{"key":"2073_CR67","first-page":"4","volume":"13","author":"JJ Lee","year":"2018","unstructured":"Lee JJ, Choo SP. The fibroblast growth factor receptor pathway in hepatocellular carcinoma. Hepatoma Res. 2018;13:4.","journal-title":"Hepatoma Res"},{"issue":"1","key":"2073_CR68","first-page":"1","volume":"5","author":"N Zheng","year":"2016","unstructured":"Zheng N, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res. 2016;5(1):1.","journal-title":"Transl Cancer Res"},{"key":"2073_CR69","doi-asserted-by":"publisher","first-page":"175628481880808","DOI":"10.1177\/1756284818808086","volume":"11","author":"G Brar","year":"2018","unstructured":"Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Ther Adv Gastroenterol. 2018;11:1756284818808086.","journal-title":"Ther Adv Gastroenterol"},{"issue":"12","key":"2073_CR70","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat I, Moreno-C\u00e0ceres J, S\u00e1nchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P. TGF-\u03b2 signalling and liver disease. he FEBS J. 2016;283(12):2219\u201332.","journal-title":"he FEBS J"},{"issue":"3","key":"2073_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/10799893.2020.1726952","volume":"40","author":"B Nair","year":"2020","unstructured":"Nair B, Nath LR. Inevitable role of TGF-\u03b21 in progression of nonalcoholic fatty liver disease. J Recept Signal Transduction. 2020;40(3):195\u2013200.","journal-title":"J Recept Signal Transduction"},{"issue":"7","key":"2073_CR72","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1073\/pnas.0705395105","volume":"105","author":"Y Tang","year":"2008","unstructured":"Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM. Progenitor\/stem cells give rise to liver cancer due to aberrant TGF-\u03b2 and IL-6 signaling. Proc Natl Acad Sci. 2008;105(7):2445\u201350.","journal-title":"Proc Natl Acad Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-02073-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02073-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:02:22Z","timestamp":1728154942000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-02073-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-02073-2","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"490"}}